Publicaciones en las que colabora con Alvaro Urbano Ispizua (15)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

2021

  1. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2007

  1. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

    British Journal of Haematology, Vol. 139, Núm. 1, pp. 70-80

2006

  1. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183

2003

  1. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

    Experimental Hematology

2002

  1. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders

    Blood, Vol. 100, Núm. 9, pp. 3121-3127

  2. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34 + selected blood cells from HLA-identical siblings

    Blood, Vol. 100, Núm. 2, pp. 724-727

2001

  1. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

    British Journal of Haematology, Vol. 114, Núm. 3, pp. 544-550

  2. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings

    Blood, Vol. 97, Núm. 2, pp. 383-387

2000

  1. The number of donor CD34+ and CD3+ cells is the most important factor for disease free survival after allogeneic transplantation of CD34+ selected cells from peripheral blood (allo-PBT/CD34+) from HLA-identical siblings

    Hematology and Cell Therapy

1998

  1. Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique

    Bone Marrow Transplantation, Vol. 22, Núm. 6, pp. 519-525

1997

  1. Trasplante alogénico de células CD34+ de sangre periférica de donantes HLA-idénticos: Experiencia española de 40 casos

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 44-45

  2. Trasplante alogénico de progenitores hemopoyéticos de sangre periférica no manipulados: Experiencia española de 79 casos

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 42-43